Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hitting the mark in hamartoma syndromes.

Advances in dermatology - 1 Jan 2006

Darling Thomas N

Abstract excerpt

The missed mark or hamartia underlying each hamartoma syndrome is a mutation in a tumor suppressor gene. This sets the stage for the development of frequent and early tumors in multiple organs. Loss of function of the tumor suppressor in neoplastic cells leads to dysregulation of signaling pathwa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, Tumor Suppressor
Share to Hamartoma Syndrome, Multiple
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Signal Transduction

Source

Identifiers

PMID: 17249302
DOI: 10.1016/j.yadr.2006.09.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17249302-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hitting the mark in hamartoma syndromes.PMID 17249302Read ↗

More than just a bump: the hamartoma syndromes.Semantic proximity Read ↗

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.Semantic proximity Read ↗

RAS Pathway Mutations and Therapeutics in Vascular Anomalies.Semantic proximity Read ↗

Hamartomas and tubers from defects in hamartin-tuberin.Semantic proximity Read ↗

Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.Semantic proximity Read ↗

Mourning Dr. Alfred G. Knudson: the two‐hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complexSemantic proximity Read ↗

TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis.Semantic proximity Read ↗

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.Semantic proximity Read ↗

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromesSemantic proximity Read ↗

Clinical and genetic analysis of patients with segmental overgrowth features and somatic mammalian target of rapamycin (mTOR) pathway disruption: Possible novel clinical issues.Semantic proximity Read ↗

Rapamycin and treatment of venous malformationsSemantic proximity Read ↗

Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.